<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673309</url>
  </required_header>
  <id_info>
    <org_study_id>00-454</org_study_id>
    <secondary_id>P50GM060338</secondary_id>
    <secondary_id>R01GM056687</secondary_id>
    <secondary_id>SHC #8660</secondary_id>
    <nct_id>NCT00673309</nct_id>
  </id_info>
  <brief_title>Assessment of Mechanisms of Improved Wound Healing</brief_title>
  <official_title>Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find ways to improve wound healing and decrease the negative
      effects of trauma from burn injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves research and the investigators hope to learn the following: how or what
      effect one or more anabolic (&quot;tissue building&quot;) agents have on muscle metabolism, wound
      healing, and immune function after severe burn. The agents include the following: growth
      hormone, insulin-like growth factor-1 in combination with its binding proteins, insulin,
      Beta-adrenergic blockers, Alpha Adrenergic Agonist, anabolic steroids such as testosterone,
      Oxandrolone and nandrolone, ketoconazole and its derivatives, dehydroepiandrosterone,
      fenofibrate, diet or the application of skin substitute.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease Hypermetabolism as Measured by Stable Isotope Infusion Study</measure>
    <time_frame>Admission to burn unit to 95% wound healing</time_frame>
    <description>Shriner's Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved Rate of Wound Healing</measure>
    <time_frame>Admission to burn unit to 95% wound healing</time_frame>
    <description>Shriner's Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Morbidity and Mortality</measure>
    <time_frame>Admission to burn unit to discharge</time_frame>
    <description>Shriner's Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Sepsis</measure>
    <time_frame>Admission to burn unit to 95% wound healing</time_frame>
    <description>Shriner's Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">644</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Growth Hormone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxandrolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGF-1/IGFBP-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGF-1/IGFBP-3 will be administered until 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Low Dose will be administered until 95% wound healing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itraconazole will be administered until 95% wound healing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Growth Hormone and Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth Hormone and Propranolol will be administered until 95% wound healing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxandrolone and Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxandrolone and Propranolol will be administered until 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo or Control will be administered until 95% wound healing</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stable Isotope Infusion study</intervention_name>
    <description>Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)</description>
    <arm_group_label>Control/Placebo</arm_group_label>
    <arm_group_label>Growth Hormone</arm_group_label>
    <arm_group_label>Growth Hormone and Propranolol</arm_group_label>
    <arm_group_label>IGF-1/IGFBP-3</arm_group_label>
    <arm_group_label>Insulin High Dose</arm_group_label>
    <arm_group_label>Insulin Low Dose</arm_group_label>
    <arm_group_label>Itraconazole</arm_group_label>
    <arm_group_label>Oxandrolone</arm_group_label>
    <arm_group_label>Oxandrolone and Propranolol</arm_group_label>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin High Dose</intervention_name>
    <description>Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.</description>
    <arm_group_label>Insulin High Dose</arm_group_label>
    <other_name>Regular Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxandrolone</intervention_name>
    <description>Oxandrolone given daily throughout hospitalization until 95% wound healing.</description>
    <arm_group_label>Oxandrolone</arm_group_label>
    <other_name>nandrolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol to be given daily throughout hospitalization until 95% wound healing.</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>Recombinant Human Growth hormone to be administered daily until 95% wound healing.</description>
    <arm_group_label>Growth Hormone</arm_group_label>
    <other_name>GH</other_name>
    <other_name>rhGH</other_name>
    <other_name>recombinant human Growth Hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Low Dose</intervention_name>
    <description>Insulin administered IV until 95% wound healing</description>
    <arm_group_label>Insulin Low Dose</arm_group_label>
    <other_name>Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGF-1/IGFBP-3</intervention_name>
    <description>Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing</description>
    <arm_group_label>IGF-1/IGFBP-3</arm_group_label>
    <other_name>Insulin Like Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole administered until 95% wound healing</description>
    <arm_group_label>Itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone and Propranolol</intervention_name>
    <description>Growth Hormone and Propranolol given until 95% wound healing</description>
    <arm_group_label>Growth Hormone and Propranolol</arm_group_label>
    <other_name>GH and Propranolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxandrolone and Propranolol</intervention_name>
    <description>Oxandrolone and Propranolol</description>
    <arm_group_label>Oxandrolone and Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo or Control</intervention_name>
    <description>Administration of Placebo or Control until 95% wound healing</description>
    <arm_group_label>Control/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is between 0 and 90 years of age

          -  Patient 18 years and older consents to participate in study protocol. If patient is
             not able to consent, consent will be obtained from closest family member or legal
             guardian. Parental permission will be obtained for patients less than 18 years of age.
             Assent will be obtained from children 7-17 years of age if child is
             physically/mentally able to do so.

          -  greater than 30% TBSA burn requiring at least 1 operation with donor sites for skin
             grafting

        Exclusion Criteria:

          -  Known history of AIDS, AIDS-related complex, Human Immunodeficiency Virus

          -  History of cancer within 5 years

          -  Tuberculosis, arthritis, cirrhosis, hyperlipidemia, bone or endocrine diseases,
             autoimmune diseases

          -  Chronic glucocorticoid or non-steroidal anti-inflammatory drug therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N. Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>November 26, 2019</results_first_submitted>
  <results_first_submitted_qc>November 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2019</results_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>burns</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Oxandrolone</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients admitted to burn unit with &gt;40% burn or greater</recruitment_details>
      <pre_assignment_details>Randomized to study drug or placebo/control</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Growth Hormone Administration</title>
          <description>Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Growth Hormone: Recombinant Human Growth hormone to be administered daily until 95% wound healing.</description>
        </group>
        <group group_id="P2">
          <title>Insulin High Dose Administration</title>
          <description>Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Insulin: Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.</description>
        </group>
        <group group_id="P3">
          <title>Oxandrolone Administration</title>
          <description>Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
oxandrolone: Oxandrolone given daily throughout hospitalization until 95% wound healing.</description>
        </group>
        <group group_id="P4">
          <title>Propranolol Administration</title>
          <description>Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Propranolol: Propranolol to be given daily throughout hospitalization until 95% wound healing.</description>
        </group>
        <group group_id="P5">
          <title>Itraconazole Administration</title>
          <description>Itraconazole administered throughout hospitalization until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Itraconazole administered throughout hospitalization until 95% wound healing.</description>
        </group>
        <group group_id="P6">
          <title>IGF-1/IGFBP-3 Comparator</title>
          <description>IGF-1/IGFBP-3 administered daily to 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
IGF-1/IGFBP-3 administered until 95% wound healing</description>
        </group>
        <group group_id="P7">
          <title>Insulin Low Dose Administration</title>
          <description>Insulin IV administered continuously through hospitalization to 95% wound healing.</description>
        </group>
        <group group_id="P8">
          <title>Growth Hormone and Propranolol Administration</title>
          <description>Growth Hormone and Propranolol administration throughout hospitalization to 95% wound healing.
Includes stable isotope infusion studies.</description>
        </group>
        <group group_id="P9">
          <title>Oxandrolone and Propranolol</title>
          <description>Oxandrolone and Propranolol administration throughout hospitalization to 95% wound healing.
Includes stable isotope infusion studies</description>
        </group>
        <group group_id="P10">
          <title>Control or Placebo</title>
          <description>Control or Placebo administered through hospitalization to 95% wound healing. Includes stable isotope infusion studies.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="35"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="13"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="35"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="13"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Shriner’s Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data. Number of Baseline Participants is UNKNOWN</population>
      <group_list>
        <group group_id="B1">
          <title>Growth Hormone Administration</title>
          <description>Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Growth Hormone: Recombinant Human Growth hormone to be administered daily until 95% wound healing.</description>
        </group>
        <group group_id="B2">
          <title>Insulin High Dose Administration</title>
          <description>Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Insulin: Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.</description>
        </group>
        <group group_id="B3">
          <title>Oxandrolone Administration</title>
          <description>Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
oxandrolone: Oxandrolone given daily throughout hospitalization until 95% wound healing.</description>
        </group>
        <group group_id="B4">
          <title>Propranolol Administration</title>
          <description>Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Propranolol: Propranolol to be given daily throughout hospitalization until 95% wound healing.</description>
        </group>
        <group group_id="B5">
          <title>Itraconazole Administration</title>
          <description>Itraconazole administered throughout hospitalization until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Itraconazole administered throughout hospitalization until 95% wound healing.</description>
        </group>
        <group group_id="B6">
          <title>IGF-1/IGFBP-3 Comparator</title>
          <description>IGF-1/IGFBP-3 administered daily to 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
IGF-1/IGFBP-3 administered until 95% wound healing</description>
        </group>
        <group group_id="B7">
          <title>Insulin Low Dose Administration</title>
          <description>Insulin IV administered continuously through hospitalization to 95% wound healing.</description>
        </group>
        <group group_id="B8">
          <title>Growth Hormone and Propranolol Administration</title>
          <description>Growth Hormone and Propranolol administration throughout hospitalization to 95% wound healing.
Includes stable isotope infusion studies.</description>
        </group>
        <group group_id="B9">
          <title>Oxandrolone and Propranolol</title>
          <description>Oxandrolone and Propranolol administration throughout hospitalization to 95% wound healing.
Includes stable isotope infusion studies</description>
        </group>
        <group group_id="B10">
          <title>Control or Placebo</title>
          <description>Control or Placebo administered through hospitalization to 95% wound healing. Includes stable isotope infusion studies.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="0"/>
            <count group_id="B10" value="0"/>
            <count group_id="B11" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Protein Net Balance</title>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decrease Hypermetabolism as Measured by Stable Isotope Infusion Study</title>
        <description>Shriner's Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
        <time_frame>Admission to burn unit to 95% wound healing</time_frame>
        <population>Shriner’s Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</population>
        <group_list>
          <group group_id="O1">
            <title>Growth Hormone</title>
            <description>Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Growth Hormone: Recombinant Human Growth hormone to be administered daily until 95% wound healing.</description>
          </group>
          <group group_id="O2">
            <title>Insulin High Dose</title>
            <description>Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Insulin High Dose: Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.</description>
          </group>
          <group group_id="O3">
            <title>Oxandrolone</title>
            <description>Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
oxandrolone: Oxandrolone given daily throughout hospitalization until 95% wound healing.</description>
          </group>
          <group group_id="O4">
            <title>Propranolol</title>
            <description>Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Propranolol: Propranolol to be given daily throughout hospitalization until 95% wound healing.</description>
          </group>
          <group group_id="O5">
            <title>IGF-1/IGFBP-3</title>
            <description>IGF-1/IGFBP-3 will be administered until 95% wound healing
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
IGF-1/IGFBP-3: Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing</description>
          </group>
          <group group_id="O6">
            <title>Insulin Low Dose</title>
            <description>Insulin Low Dose will be administered until 95% wound healing.
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Insulin Low Dose: Insulin administered IV until 95% wound healing</description>
          </group>
          <group group_id="O7">
            <title>Itraconazole</title>
            <description>Itraconazole will be administered until 95% wound healing.
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Itraconazole: Itraconazole administered until 95% wound healing</description>
          </group>
          <group group_id="O8">
            <title>Growth Hormone and Propranolol</title>
            <description>Growth Hormone and Propranolol will be administered until 95% wound healing.
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Growth Hormone and Propranolol: Growth Hormone and Propranolol given until 95% wound healing</description>
          </group>
          <group group_id="O9">
            <title>Oxandrolone and Propranolol</title>
            <description>Oxandrolone and Propranolol will be administered until 95% wound healing
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Oxandrolone and Propranolol: Oxandrolone and Propranolol</description>
          </group>
          <group group_id="O10">
            <title>Control/Placebo</title>
            <description>Placebo or Control will be administered until 95% wound healing
Stable Isotope Infusion study: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Placebo or Control: Administration of Placebo or Control until 95% wound healing</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease Hypermetabolism as Measured by Stable Isotope Infusion Study</title>
          <description>Shriner's Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
          <population>Shriner’s Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improved Rate of Wound Healing</title>
        <description>Shriner's Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
        <time_frame>Admission to burn unit to 95% wound healing</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Morbidity and Mortality</title>
        <description>Shriner's Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
        <time_frame>Admission to burn unit to discharge</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Sepsis</title>
        <description>Shriner's Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
        <time_frame>Admission to burn unit to 95% wound healing</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <description>unknown - Shriner’s Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Shriner’s Burn Hospital revoked access to study-related data.. We are unable to submit the additional information or results-data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Herndon, MD</name_or_title>
      <organization>University of Texas Medical Branch</organization>
      <phone>409-770-6731</phone>
      <email>dherndon@utmb.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

